QXO Proposes Full Slate of Independent Directors for Election at Beacon Roofing Supply's 2025 Annual Meeting
QXO, Inc. (NYSE: QXO) announced today that it has informed Beacon Roofing Supply, Inc. (Nasdaq: BECN) that it will propose 10 ...
QXO Receives Antitrust Clearance for Acquisition of Beacon Roofing Supply
Calls on Beacon to Remove Shareholder-Unfriendly Poison PillGREENWICH, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- QXO, Inc.
QXO proposes to replace full slate of Beacon Roofing directors after offer rejected
QXO late last month launched a tender offer to buy Beacon ( BECN) for $124.25 a share after its $11 billion takeover was ...
QXO to propose 10 independent director nominees to replace Beacon board
QXO (QXO) announced that it has informed Beacon (BECN) that it will propose 10 independent director nominees at Beacon’s 2025 annual meeting of ...
MDM8m
QXO Unveils Slate of Directors to Replace Beacon’s, Gains Antitrust Clearance
The also company called on Beacon to remove its “poison pill” aimed to hold off QXO’s takeover bid from going to a ...
MDM7h
QXO Gets Antitrust Clearance for Beacon Acquisition
The also company called on Beacon to remove its “poison pill” aimed to hold off QXO’s takeover bid from going to a ...
QXO receives antitrust clearance for acquisition of Beacon
QXO (QXO) announced that it has obtained antitrust clearance in both the U.S. and Canada for its acquisition of Beacon Roofing Supply (BECN), ...
QXO, Inc.: QXO Receives Antitrust Clearance for Acquisition of Beacon Roofing Supply
QXO, Inc. (NYSE: QXO) announced today that it has obtained antitrust clearance in both the U.S. and Canada for its acquisition of Beacon Roofing Supply ...
QXO secures antitrust clearance for Beacon acquisition
GREENWICH, Conn. - QXO, Inc. (NYSE: QXO) has received antitrust clearance from both the U.S. and Canada for its planned acquisition of Beacon Roofing Supply, Inc. (Nasdaq: NASDAQ:BECN), it was ...
manilatimes32m
Crane NXT Announces Fourth Quarter and Full Year 2024 Results; Raises Annual Dividend by 6%
Fourth quarter 2024 sales were $399.1 million, an increase of $42.2 million, or 11.8%, compared with the fourth quarter of ...
manilatimes9h
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML ...
yr.no22h
Beacon Bay
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...